JP6367944B2 - トランスアミナーゼ及びその応用 - Google Patents
トランスアミナーゼ及びその応用 Download PDFInfo
- Publication number
- JP6367944B2 JP6367944B2 JP2016535181A JP2016535181A JP6367944B2 JP 6367944 B2 JP6367944 B2 JP 6367944B2 JP 2016535181 A JP2016535181 A JP 2016535181A JP 2016535181 A JP2016535181 A JP 2016535181A JP 6367944 B2 JP6367944 B2 JP 6367944B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- transaminase
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000340 Transaminases Proteins 0.000 title claims description 81
- 102000003929 Transaminases Human genes 0.000 title claims description 70
- 150000001413 amino acids Chemical group 0.000 claims description 59
- 239000002773 nucleotide Substances 0.000 claims description 59
- 125000003729 nucleotide group Chemical group 0.000 claims description 59
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- 238000006243 chemical reaction Methods 0.000 claims description 28
- 150000001412 amines Chemical class 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- -1 ketone compound Chemical class 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000002837 carbocyclic group Chemical group 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 230000003196 chaotropic effect Effects 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 7
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 7
- 229960001327 pyridoxal phosphate Drugs 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical group CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000000172 C5-C10 aryl group Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 239000012634 fragment Substances 0.000 description 50
- 230000000694 effects Effects 0.000 description 27
- 239000000047 product Substances 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 23
- 239000002994 raw material Substances 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- 230000003197 catalytic effect Effects 0.000 description 17
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 12
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 11
- 229960000723 ampicillin Drugs 0.000 description 11
- 229910052781 Neptunium Inorganic materials 0.000 description 10
- LFNLGNPSGWYGGD-UHFFFAOYSA-N neptunium atom Chemical compound [Np] LFNLGNPSGWYGGD-UHFFFAOYSA-N 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 241001465318 Aspergillus terreus Species 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 238000009630 liquid culture Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000004817 gas chromatography Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000001976 enzyme digestion Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- XMCRWEBERCXJCH-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1Cl XMCRWEBERCXJCH-UHFFFAOYSA-N 0.000 description 4
- XSAYZAUNJMRRIR-UHFFFAOYSA-N 2-acetylnaphthalene Chemical compound C1=CC=CC2=CC(C(=O)C)=CC=C21 XSAYZAUNJMRRIR-UHFFFAOYSA-N 0.000 description 4
- 241000228212 Aspergillus Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- KHSYYLCXQKCYQX-SECBINFHSA-N (1r)-1-naphthalen-2-ylethanamine Chemical compound C1=CC=CC2=CC([C@H](N)C)=CC=C21 KHSYYLCXQKCYQX-SECBINFHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- RIFXIGDBUBXKEI-UHFFFAOYSA-N tert-butyl 3-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(=O)C1 RIFXIGDBUBXKEI-UHFFFAOYSA-N 0.000 description 2
- 238000005891 transamination reaction Methods 0.000 description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 1
- 241001619535 Hyphomonas neptunium Species 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005011 alkyl ether group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003304 ruthenium compounds Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/001—Amines; Imines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01018—Beta-alanine-pyruvate transaminase (2.6.1.18)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
用語「選択的/任意」又は「選択的に/任意に」はその後に記載の事件又は状況が発生する可能性があれば発生しない可能性もあることを表し、このような記載は該当事件又は状況が発生する場合と発生しない場合とを含む。例えば、以下の定義によって、「選択的に置換されたアルキル基」は「置換されていないアルキル基」(置換基によって置換されていないアルキル基)又は「置換されたアルキル基」(置換基によって置換されたアルキル基)とを表す。
本発明のトランスアミナーゼAH−TACM33の製造方法の具体的な工程は以下のとおりである:
生工生物工程(上海)有限会社に依頼して、アスペルギルス・テレウスとヒポモナスネプチュニウムから由来のトランスアミナーゼ遺伝子taAT(アスペルギルス・テレウス)(そのヌクレオチド配列は配列表中のSEQ ID NO.:5に示す遺伝子配列であって、アミノ酸配列はSEQ ID NO.:23に示すとおりである)とtaHN(ヒポモナスネプチュニウム)(そのヌクレオチド配列は配列表中のSEQ ID NO.:6に示す遺伝子配列であって、アミノ酸配列はSEQ ID NO.:24に示すとおりである)とを全遺伝子合成し、合成されたtaAT遺伝子とtaHNをベクターpUC57に接続して組換えプラスミドpUC57−taATとpUC57−taHNを得た。その後、NdeIとXhoI制限性エンドヌクレアーゼを利用して、組換えプラスミドpUC57−taATとpUC57−taHNを同時に酵素消化を行って、ゲル回収を経て純化された回収破片taATとtaHNを得て、後続のPCR の鋳型とした。
アスペルギルス・テレウス由来のトランスアミナーゼ遺伝子に基づいて設計した特異性プライマーは以下のとおりである:
taAT A: 5’−CCGCTCGAGGTTACGCTCGTTGTAGTCAATTTC−3’ (SEQ ID NO.:7)
taAT S: 5’−GGAATTCCATATGGCGTCTATGGACAAAG−3’ (SEQ ID NO.:8)
taHN A: 5’−CCGCTCGAGCGGTGCATAGGTTACCGGTTC−3’ (SEQ ID NO.:9)
taHN S:5’−GGAATTCCATATGCTGACCTTCCAAAAAGTACTGAC−3’ (SEQ ID NO.:10)
CM31A:5’−GAACTTCAGACCGCGGGTGACAATCAG−3’ (SEQ ID NO.:11)
CM31S:5’− CACCCGCGGTCTGAAGTTCCTGC −3’ (SEQ ID NO.:12)
CM32A:5’− CGGCGGAACACGACGAACGGTACG −3’ (SEQ ID NO.:13)
CM32S:5’− TTCGTCGTACTCCGCCGGGCGCAC −3’(SEQ ID NO.:14)
CM33A:5’− TAGCCTGCGCCCTCGGTCAGGTGAG −3’ (SEQ ID NO.:15)
CM33S:5’− GACCGAGGGCGCAGGCTACAATATC −3’ (SEQ ID NO.:16)
CM34A:5’− CCCTTCAGACCACGCGTAACGATGATC −3’ (SEQ ID NO.:17)
CM34S:5’− TTACGCGTGGTCTGAAGGGTGTGCGTG −3’ (SEQ ID NO.:18)
CM35A:5’− CCAGGCGGAGTACGACGTACAGTACGAG −3’ (SEQ ID NO.:19)
CM35S:5’− TACGTCGTGTTCCGCCTGGCGCAATC −3’ (SEQ ID NO.:20)
CM36A:5’− GCCGCTGCCTTCCGTCGCGTTACC −3’ (SEQ ID NO.:21)
CM36S:5’− GACGGAAGGCAGCGGCTTCAACATC −3’ (SEQ ID NO.:22)
アスペルギルス・テレウス由来のトランスアミナーゼ遺伝子に基づいて設計した特異性プライマーtaAT S(順方向プライマー)と上記6対のプライマーの中の三つの逆方向プライマー(CM31A、CM32A、CM33A)の中のいづれか一つの逆方向プライマーとを組み合せし、アスペルギルス・テレウス由来のトランスアミナーゼ遺伝子の破片を拡張し、又は、taHN A(逆方向プライマー)と上記6対のプライマーの中の三つの順方向プライマー(CM36S、CM35S、CM34S)の中的いづれか一つとを組み合せして、ヒポモナスネプチュニウム由来のトランスアミナーゼ遺伝子の破片を拡張した。その後、上記拡張して得た出所の異なる二つの破片を整合させて、改善されたトランスアミナーゼ遺伝子を得た。
(1)破片Aの取得:上記回収破片taATをPCR 鋳型とし、taAT SとCM33Aをプライマーとして、PCR 拡張を行って、産物をゲル回収して純化すると、破片Aである。
PCR体系:破片A 1μL、破片B 1μL、PCR MIX 5μL、ddH2O 4.5μL;
PCR プログラム:95℃ 3min;(95℃ 30s、57℃ 30s、72℃ 90s、5個循環);72℃ 1min;
体系にプライマーtaAT SとtaHN Aをそれぞれ 0.2μL添加する。
PCR プログラム:95℃ 3min;(95℃ 30s、57℃ 30s、72℃ 90s、30個循環);72℃ 10min。
反応瓶に1g主原料(N−Boc−3−ピペリドン、CAS:98977−36−7)と1mL ジメチルスルホキシドを投入し、原料を分散させた後、50mL 0.2mol/Lの氷浴条件で濃い塩酸でpHを9.3〜9.5まで調節したトリエタノールアミン緩衝液、0.765g イソプロピルアミン、0.01gピリドキサールリン酸、0.01g上記AH−TACM33トランスアミナーゼを添加し、体系のpHは9.5で、30℃の恒温で12h攪拌した。体系のpHを2N NaOHを用いて10以上に調節し、酢酸エチルを利用して二回抽出し、有機相を乾燥、ろ過、濃縮して粗生成物を得て(中国語名称:(R)−1−N−Boc−3−アミノ基ピペリジン、CAS:188111−79−7)、ガスクロマトグラフィー(GC)検定の結果、形質転換率は90%で、e.e値は100%であった。
得られた製品の核磁気データは、1H−NMR(300 MHz、CDCl3)δ 4.00−3.78(m,2h)、3.80(m,2h)、3.60(m,1H)、1.90(m,1H)、1.70(m,1H)、1.60−1.40(m,12H)、1.30(m,1H)ppmである。
反応瓶に0.1g主原料(2,4−ジクロロアセトフェノン、CAS: 2234−16−4)と1.5 mLポリエチレングリコールPEG−400を投入し、原料を分散させた後、23.5mLリン酸塩緩衝液(pH8.0)、0.031 gイソプロピルアミン、0.0075gピリドキサールリン酸、0.02g 上記AH−TACM33トランスアミナーゼを添加し、体系のpHは8.0で、45℃の恒温で20h攪拌した。体系のpHを2N NaOHを利用して10以上に調節し、酢酸エチルを利用して二回抽出し、有機相を乾燥、ろ過、濃縮して粗生成物([(R)−(+)−1−(2,4−ジクロロフェニル)エチル]アミン、CAS:133773−29−2)を得て、GC検定の結果、形質転換率は82%で、e.e値は100%であった。
本発明のトランスアミナーゼAH−TACM32の製造方法は以下の工程を含む。
実施例1に記載の方法に従って組換えプラスミドpUC57−taAT とpUC57−taHNを取得した。NdeIとXhoI制限性エンドヌクレアーゼを利用して、組換えプラスミドpUC57−taATとpUC57−taHNとを同時に酵素消化を行って、ゲル回収し純化して、回収破片taATとtaHNを得て、次のPCRの鋳型とした。
実施例1と同じである。
(1)破片Eの取得:上記回収破片taATをPCR 鋳型とし、taAT SとCM32Aをプライマーとし、PCR 拡張を行って、産物をゲル回収して純化すると、破片Eである。
反応瓶に0.1g主原料(2−アセトナフトン、CAS:93−08−3)と1mLポリエチレングリコールPEG−400を投入し、原料を分散させた後、24mLリン酸塩緩衝液(pHが7.0)、0.17gイソプロピルアミン、0.01gピリドキサールリン酸、0.004g上記AH−TACM32トランスアミナーゼを添加し、体系のpHは7.0で、20℃の恒温で48h攪拌した。体系のpHを2N NaOHを利用して10以上に調節し、酢酸エチルを利用して二回抽出し、有機相を乾燥、ろ過、濃縮して粗生成物(((R)−(+)−1−(2−ナフチル)エチルアミン、CAS:3906−16−9)を得て、GC検定の結果、形質転換率は20%で、e.e値は100%であった。
アミノ酸配列がSEQ ID NO.:2であるトランスアミナーゼであるAH−TACM32を基に、該トランスアミナーゼを第38位のロイシンに突然変異させて、ロイシンをイソロイシンに置換して、配列がSEQ ID NO.:25であるトランスアミナーゼを得た。
突然変異体菌液をアンピシリンを最終濃度50μg/mL含有するLB液体培養基質100mLに接種し、37℃、180r/minで、OD600値が0.6〜0.8になるまで振動培養し、最終濃度が0.2mMになるまでIPTGを添加し、培養液を25℃にして誘導発現し、同時に、IPTG誘導剤を添加していない培養液を陰性対照とした。16h誘導した後、菌液を取り出して、12000r/minで、5min遠心処理して菌体を収集した。0.5gの菌体を計って再懸濁させ2.5mL 0.1Mリン酸塩緩衝液(pH8.0)菌体と超音波破砕器で細胞破砕し、超音波パラメータはプローブ直径が6mmで、出力が200Wで、2s動作し、6s間欠的に休憩し、合計で10min行って、超音波処理後に4℃、12000r/minで、20min遠心処理して超音波上澄みと沈殿物を得て、上澄みは酵素活性のテスト反応へ用いた。
Claims (11)
- アミノ酸配列が、
a)SEQ ID NO.:4に示すアミノ酸配列、
b)SEQ ID NO.:2に示すアミノ酸配列中の第38位のロイシンをイソロイシンに置換したアミノ酸配列
から選ばれた一つであることを特徴とするトランスアミナーゼ。 - 請求項1に記載のトランスアミナーゼの符号化を行うことを特徴とするヌクレオチド。
- SEQ ID NO.:3又は25に示すヌクレオチド配列から選ばれたことを特徴とする請求項2に記載のヌクレオチド。
- 請求項2または3に記載のヌクレオチドが有効に接続されていることを特徴とする組換えベクター。
- 請求項4に記載の組換えベクターを有することを特徴とする宿主細胞。
- ケトン系化合物と、請求項1に記載のトランスアミナーゼと、ピリドキサールリン酸と、アミノ基供与体とを、反応系で反応させてキラルアミンを得ることを特徴とするキラルアミンの合成方法。
- 上記ケトン系化合物は
- 上記反応系にカオトロピック剤をさらに含有し、上記カオトロピック剤はジメチルスルホキシド又はポリエチレングリコールであることを特徴とする請求項6または7に記載の方法。
- 上記ポリエチレングリコールがPEG−400であることを特徴とする請求項9に記載の方法。
- 上記C1〜C8アルキル基はC1〜C8直鎖アルキル基で、C5〜C10ヘテロアリール基はピリジン基で、アルコキシル基はC1〜C6アルコキシル基で、C5〜C10複素環基の中の複素環基はピペリジンで、C5〜C10アリール基の中のアリール基、C5〜C10ヘテロアリール基の中のヘテロアリール基、C5〜C10炭素環基中の炭素環基又はC5〜C10複素環基中の複素環基の置換基はそれぞれ独自に、C1〜C6直鎖アルキル基、C1〜C6アルコキシル基であって、アミノ基供与体はイソプロピルアミン又はD−アラニンであることを特徴とする請求項7に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310611503 | 2013-11-26 | ||
CN201310611503.8 | 2013-11-26 | ||
PCT/CN2014/090080 WO2015078267A1 (zh) | 2013-11-26 | 2014-10-31 | 转氨酶及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016537992A JP2016537992A (ja) | 2016-12-08 |
JP6367944B2 true JP6367944B2 (ja) | 2018-08-01 |
Family
ID=52402901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016535181A Active JP6367944B2 (ja) | 2013-11-26 | 2014-10-31 | トランスアミナーゼ及びその応用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10131926B2 (ja) |
EP (1) | EP3075847B1 (ja) |
JP (1) | JP6367944B2 (ja) |
KR (1) | KR101910259B1 (ja) |
CN (1) | CN104328094B (ja) |
ES (1) | ES2734579T3 (ja) |
WO (1) | WO2015078267A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104774830B (zh) * | 2015-03-27 | 2018-05-08 | 成都百特万合医药科技有限公司 | 一种转氨酶的固定化方法 |
PL3283622T3 (pl) * | 2015-04-16 | 2019-11-29 | Hoffmann La Roche | Mutanty transaminazy oraz związane z nimi sposoby i zastosowania |
CN106834244B (zh) * | 2016-11-04 | 2021-07-06 | 凯莱英医药集团(天津)股份有限公司 | 脯氨酸羟化酶及其应用 |
CN106754806B (zh) * | 2016-12-20 | 2020-04-14 | 尚科生物医药(上海)有限公司 | 一种改进的转氨酶及其在(r)-3-氨基丁醇制备上的应用 |
CN109234327A (zh) * | 2017-07-11 | 2019-01-18 | 上海弈柯莱生物医药科技有限公司 | 一种立体选择性的转氨酶在不对称合成手性胺中的应用 |
CN107805648B (zh) * | 2017-10-10 | 2020-09-11 | 凯莱英生命科学技术(天津)有限公司 | 制备具有多个手性中心的胺化合物的方法 |
CN108048419B (zh) * | 2017-11-15 | 2020-10-23 | 凯莱英生命科学技术(天津)有限公司 | 转氨酶突变体及其应用 |
CN109486784B (zh) * | 2018-11-30 | 2020-06-09 | 江南大学 | 一种能催化西他沙星五元环关键中间体的ω-转氨酶突变体 |
CN109486787A (zh) * | 2018-12-23 | 2019-03-19 | 尚科生物医药(上海)有限公司 | 一种pH稳定性提高的转氨酶突变体 |
CN111117979B (zh) * | 2020-01-14 | 2020-08-21 | 中国科学院苏州生物医学工程技术研究所 | 转氨酶突变体、酶制剂、重组载体、重组细胞及其制备方法和应用 |
CN111363732B (zh) * | 2020-03-12 | 2023-05-23 | 卡柔恩赛生物技术湖北有限公司 | 来源于土曲霉菌nih2624的转氨酶突变体及其应用 |
CN111349666A (zh) * | 2020-04-10 | 2020-06-30 | 宁波酶赛生物工程有限公司 | 一种苯乙胺的生产方法及其设备 |
CN112522228B (zh) * | 2020-09-21 | 2023-12-29 | 江苏海洋大学 | 一种来源于氨氧化假诺卡氏单胞菌的r-转氨酶及其合成方法 |
CN113881720B (zh) * | 2020-12-31 | 2023-08-25 | 上海合全药物研发有限公司 | 一种转氨酶及使用其进行催化制备的方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07289252A (ja) | 1994-04-28 | 1995-11-07 | Sumitomo Chem Co Ltd | チトクロムp450の一原子酸素添加活性の向上方法 |
JPH1075787A (ja) * | 1996-09-02 | 1998-03-24 | Asahi Chem Ind Co Ltd | 変異型アラニンアミノトランスフェラーゼおよびその製造法 |
EP1041150A1 (en) | 1999-03-19 | 2000-10-04 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Hybrid synthetase, fungus/bacterium strain, hybrid peptide and compositions containing same |
JP2004033161A (ja) | 2002-07-05 | 2004-02-05 | Tosoh Corp | アミノトランスフェラーゼ |
EP1818411A1 (en) * | 2006-02-13 | 2007-08-15 | Lonza AG | Process for the preparation of optically active chiral amines |
EP1897956A1 (en) | 2006-09-06 | 2008-03-12 | Lonza AG | Process for preparation of optically active amines by optical resolution of racemic amines employing a bacterial omega-transaminase |
JP5563990B2 (ja) * | 2008-01-03 | 2014-07-30 | ヴェレニウム コーポレイション | トランスフェラーゼおよびオキシドレダクターゼ、それらをコードする核酸並びにそれらを製造および使用する方法 |
EP2358873B2 (en) | 2008-12-15 | 2018-02-21 | Danisco US Inc. | Hybrid alpha-amylases |
HUE052297T2 (hu) | 2009-01-08 | 2021-04-28 | Codexis Inc | Transzamináz polipeptidek |
US8577622B2 (en) * | 2009-09-02 | 2013-11-05 | Lonza Ag | Process for the identification and preparation of a (R)-specific omega-transaminase |
PT2593556T (pt) * | 2010-07-14 | 2017-12-11 | Dpx Holdings Bv | Método enzimático de (r)-aminação seletiva |
CN103534353B (zh) | 2011-03-11 | 2016-08-17 | 株式会社钟化 | 修饰型氨基转移酶、其基因以及利用它们的光学活性氨基化合物的制造方法 |
CN103194501B (zh) * | 2013-03-29 | 2015-05-27 | 凯莱英医药集团(天津)股份有限公司 | 利用氨基转移酶合成手性环状烷基氨基酸的方法 |
-
2014
- 2014-10-31 CN CN201410606252.9A patent/CN104328094B/zh active Active
- 2014-10-31 EP EP14865656.4A patent/EP3075847B1/en not_active Not-in-force
- 2014-10-31 KR KR1020167017037A patent/KR101910259B1/ko active IP Right Grant
- 2014-10-31 JP JP2016535181A patent/JP6367944B2/ja active Active
- 2014-10-31 ES ES14865656T patent/ES2734579T3/es active Active
- 2014-10-31 WO PCT/CN2014/090080 patent/WO2015078267A1/zh active Application Filing
- 2014-10-31 US US15/039,804 patent/US10131926B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3075847A1 (en) | 2016-10-05 |
WO2015078267A1 (zh) | 2015-06-04 |
US20170073713A1 (en) | 2017-03-16 |
US10131926B2 (en) | 2018-11-20 |
ES2734579T3 (es) | 2019-12-10 |
KR101910259B1 (ko) | 2018-12-19 |
KR20160103994A (ko) | 2016-09-02 |
JP2016537992A (ja) | 2016-12-08 |
CN104328094A (zh) | 2015-02-04 |
CN104328094B (zh) | 2017-08-04 |
EP3075847B1 (en) | 2019-05-15 |
EP3075847A4 (en) | 2017-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6367944B2 (ja) | トランスアミナーゼ及びその応用 | |
JP2016537991A (ja) | R型ω−トランスアミナーゼ及びその応用 | |
CN110914417B (zh) | 一种立体选择性的转氨酶在不对称合成手性胺中的应用 | |
CN105018440B (zh) | 一种转氨酶及其在合成西他列汀中间体中的应用 | |
US20200332321A1 (en) | Engineered transaminase polypeptides and uses thereof | |
CN110846291B (zh) | 热稳定性提高的胺脱氢酶突变体及其基因工程菌的构建和应用 | |
CN106701698A (zh) | 羰基还原酶、突变体及其在制备抗真菌类药物中间体中的应用 | |
US11512303B2 (en) | Engineered polypeptides and their applications in the synthesis of beta-hydroxy-alpha-amino acids | |
CN105567652B (zh) | 一种酮还原酶及其在不对称合成手性羟基化合物中的应用 | |
JP2017108740A (ja) | 改変型meso−ジアミノピメリン酸脱水素酵素 | |
WO2016198660A1 (en) | Transaminases | |
CN112522228B (zh) | 一种来源于氨氧化假诺卡氏单胞菌的r-转氨酶及其合成方法 | |
CN105408489B (zh) | 用于制备去甲伪麻黄碱的方法 | |
CN105018439B (zh) | 一种羰基还原酶及其在合成手性羟基化合物中的应用 | |
CN110951711B (zh) | 一种具有降解手性酯活性的酯酶及其编码基因和应用 | |
CN109402188B (zh) | 一种来自短小芽孢杆菌的ω-转氨酶及在生物胺化中的应用 | |
CN107119035A (zh) | 苯丙氨酸变位酶、编码基因、重组载体、宿主细胞、多重pcr引物及它们的应用 | |
CN118599796A (zh) | 一种赖氨酸胺脱氢酶突变体及其在手性胺类化合物合成中的应用 | |
CN115807046A (zh) | 一种转氨酶催化合成卡巴拉汀药物中间体的方法 | |
CN111484986A (zh) | 一种短链脱氢酶及应用 | |
WO2007148514A1 (ja) | 4-ヒドロキシ-2-キノリノン類の酵素合成法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160526 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170327 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170627 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170828 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180528 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180611 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180705 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6367944 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |